Oncology drugs company Champions Oncology Inc (Nasdaq:CSBR) disclosed on Thursday loss from operations of USD619,000 for the first quarter ended 31 July 2017.
This marks an improvement of USD1.9m or (75.5%) when compared with the higher loss from operations of USD2.5m in the first quarter of fiscal 2017.
Revenue of USD5m were generated for the first quarter of fiscal 2018, up 37.1% over revenues of USD3.7m for the first quarter 2017.
Research and development (R&D) expense of USD1.1m was recorded for the three months ended 31 July 2017, a decline of USD100,000, or (7.7%) from R&D of USD1.2m for the three months ended 31 July 2016.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government